Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed Chronic Lymphocytic Leukemia (CLL)
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Ability to swallow oral medication
You may not be if
Known hepatitis B virus, hepatitis C virus or HIV infection
Primary central nervous system lymphoma or known intracranial involvement
Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months
Clareo Health | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
